과제정보
This research was supported by the NRF-2014R1A6A 1029617, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education.
참고문헌
- Bai, L., Li, A., Gong, C., Ning, X. and Wang, Z. (2020) Protective effect of rutin against bleomycin induced lung fibrosis: involvement of TGF-β1/α-SMA/Col I and III pathway. BioFactors 46, 637-644. https://doi.org/10.1002/biof.1629
- Boyapally, R., Pulivendala, G., Bale, S. and Godugu, C. (2019) Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins &Wnt/β-catenin signaling: a drug repurposing study. Life Sci. 220, 8-20. https://doi.org/10.1016/j.lfs.2018.12.061
- Canestaro, W. J., Forrester, S. H., Raghu, G., Ho, L. and Devine, B. E. (2016) Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 149, 756-766. https://doi.org/10.1016/j.chest.2015.11.013
- Chen, C., Wang, Y. Y., Wang, Y. X., Cheng, M. Q., Yin, J. B., Zhang, X. and Hong, Z. P. (2018) Gentiopicroside ameliorates bleomycin-induced pulmonary fibrosis in mice via inhibiting inflammatory and fibrotic process. Biochem. Biophys. Res. Commun. 495, 2396-2403. https://doi.org/10.1016/j.bbrc.2017.12.112
- Chen, L. and Zhao, W. (2016) Apigenin protects against bleomycin-induced lung fibrosis in rats. Exp. Ther. Med. 11, 230-234. https://doi.org/10.3892/etm.2015.2885
- Chun-Bin, S., Yi, Y., Qin-Yi, W., Yang, L., Jing-Ze, Y., Hai-Jing, X., SiQi, Z., Jiong, H., Jing, W., Fei-Yu, L., Jin-Yuan, Y., Jia-Li, Y. and Zhong-Shan, Y. (2020) The main active components of Curcuma zedoaria reduces collagen deposition in human lung fibroblast via autophagy. Mol. Immunol. 124, 109-116. https://doi.org/10.1016/j.molimm.2020.05.017
- Cui, Y., Jiang, L., Yu, R., Shao, Y., Mei, L. and Tao, Y. (2019) β-carboline alkaloids attenuate bleomycin induced pulmonary fibrosis in mice through inhibiting NF-kb/p65 phosphorylation and epithelial-mesenchymal transition. J. Ethnopharmacol. 243, 112096.
- Divya, T., Velavan, B. and Sudhandiran, G. (2018) Regulation of transforming growth factor-β/Smad-mediated epithelial-mesenchymal transition by celastrol provides protection against bleomycin-induced pulmonary fibrosis. Basic Clin. Pharmacol. Toxicol. 123, 122-129. https://doi.org/10.1111/bcpt.12975
- Dong, S. H., Liu, Y. W., Wei, F., Tan, H. Z. and Han, Z. D. (2017) Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomed. Pharmacother. 89, 1297-1309. https://doi.org/10.1016/j.biopha.2017.03.005
- Fu, Y., Zhao, P., Xie, Z., Wang, L. and Chen, S. (2018) Oridonin inhibits myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by regulating transforming growth factor β (TGFβ)/Smad pathway. Med. Sci. Monit. 24, 7548-7555. https://doi.org/10.12659/MSM.912740
- Garcia-Sancho, C., Buendia-Roldan. I., Fernandez-Plata, M. R., Navarro, C., Perez-Padilla, R., Vargas, M. H., Loyd, J. E. and Selman, M. (2011) Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir. Med. 105, 1902-1907. https://doi.org/10.1016/j.rmed.2011.08.022
- Gan, C., Zhang, Q., Liu, H., Wang, G., Wang, L., Li, Y., Tan, Z., Yin, W., Yao, Y., Xie, Y., Ouyang, L., Yu, L. and Ye, T. (2022) Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study. Respir Res. 23, 32.
- Guan, C., Qiao, S., Lv, Q., Cao, N., Wang, K., Dai, Y. and Wei, Z. (2018) Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-gamma and subsequent expression of HGF in colons. Toxicol. Appl. Pharmacol. 343, 1-15. https://doi.org/10.1016/j.taap.2018.02.001
- Gungor, H., Ekici, M., Onder Karayigit, M., Turgut, N. H., Kara, H. and Arslanbas, E. (2020) Zingerone ameliorates oxidative stress and inflammation in bleomycin-induced pulmonary fibrosis: modulation of the expression of TGF-β1 and iNOS. Naunyn-Schmiedeberg's Arch. Pharmacol. 393, 1659-1670. https://doi.org/10.1007/s00210-020-01881-7
- Harari, S. and Caminati, A. (2010) IPF: new insight on pathogenesis and treatment. Allergy 65, 537-553. https://doi.org/10.1111/j.1398-9995.2009.02305.x
- Iyer, S. N., Gurujeyalakshmi, G. and Giri, S. N. (1999) Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367-373.
- Jiang, F., Li, M., Wang, H., Ding, B., Zhang, C., Ding, Z., Yu, X. and Lv, G. (2019) Coelonin, an anti-inflammation active component of Bletilla striata and its potential mechanism. Int. J. Mol. Sci. 20, 4422.
- Karkale, S., Khurana, A., Saifi, M. A., Godugu, C. and Talla, V. (2018) Andrographolide ameliorates silica induced pulmonary fibrosis. Int. Immunopharmacol. 62, 191-202. https://doi.org/10.1016/j.intimp.2018.07.012
- King, T. E., Jr., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J. and Noble, P. W. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083-2092. https://doi.org/10.1056/NEJMoa1402582
- Kreuter, M., Bonella, M., Wijsenbeek, M., Maher, T. M. and Spagnolo, P. (2015) Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. BioMed Res. Int. 2015, 329481.
- Kropski, J. A., Mitchell, D. B., Markin, C., Polosukhin, V. V., Choi, L., Johnson, J. E., Lawson, W. E., Phillips, J. A., 3rd, Cogan, J. D., Blackwell, T. S. and Loyd, J. E. (2014) A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 146, e1-e7. https://doi.org/10.1378/chest.13-2224
- Kyung, S. Y., Kim, D. Y., Yoon, J. Y., Son, E. S., Kim, Y. J., Park, J. W. and Jeong, S. H. (2018) Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacol.Toxicol. 19, 13.
- Li, C., Lu, Y., Du, S., Li, S., Zhang, Y., Liu, F., Chen, Y., Weng, D. and Chen, J. (2017a) Dioscin exerts protective effects against crystalline silica-induced pulmonary fibrosis in mice. Theranostics 7, 4255-4275. https://doi.org/10.7150/thno.20270
- Li, C., Yu, Y., Li, W., Liu, B., Jiao, X., Song, X., Lv, C. and Qin, S. (2017b) Phycocyanin attenuates pulmonary fibrosis via the TLR2-MyD88-NFkappaB signaling pathway. Sci. Rep. 7, 5843.
- Li, R. S., Xu, G. H., Cao, J., Liu, B., Xie, H. F., Ishii, Y. and Zhang, C. F. (2019) α-Mangostin ameliorates bleomycin-induced pulmonary fibrosis in mice partly through activating adenosine 5'-monophosphate-activated protein kinase. Front. Pharmacol. 10, 1305.
- Li, X., Lu, C., Liu, S., Shuaishuai, L., Su, C., Xiao, T., Bi, Z., Sheng, P., Huang, M., Liu, X., Wei, Y., Zhao, L., Miao, S., Mao, J., Huang, K., Gao, S., Liu, N., Qi, M., Liu, T., Qin, S., Wei, L., Sun, T., Ning, W., Yang, G., Zhou, H. and Yang, C. (2018a) Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway. Eur. J. Med. Chem. 157, 229-247. https://doi.org/10.1016/j.ejmech.2018.07.074
- Li, X., Yu, H., Liang, L., Bi, Z., Wang, Y., Gao, S., Wang, M., Li, H., Miao, Y., Deng, R., Ma, L., Luan, J., Li, S., Liu, M., Lin, J., Zhou, H. and Yang, C. (2020) Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling via targeting HSP90β. Biochem. Pharmacol. 178, 114097.
- Li, X. H., Xiao, T., Yang, J. H., Qin, Y., Gao, J. J., Liu, H. J. and Zhou, H. G. (2018b) Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-kappaB/Snail signaling pathway. Respir. Res. 19, 111.
- Liu, M., Xu, H., Zhang, L., Zhang, C., Yang, L., Ma, E., Liu, L. and Li, Y. (2018) Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem. Biophys. Res. Commun. 495, 325-331. https://doi.org/10.1016/j.bbrc.2017.11.014
- Loomis-King, H., Flaherty, K. R. and Moore, B. B. (2013) Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr. Opin. Pharmacol. 13, 377-385. https://doi.org/10.1016/j.coph.2013.03.015
- Ma, H., Wu, X., Li, Y. and Xia, Y. (2022) Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Front. Pharmacol. 13, 963054.
- Maher, T. M., Wells, A. U. and Laurent, G. J. (2007) Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur. Respir. J. 30, 835-839. https://doi.org/10.1183/09031936.00069307
- Mathai, S. K., Schwartz, D. A. and Warg, L. A. (2014) Genetic susceptibility and pulmonary fibrosis. Curr. Opin. Pulm. Med. 20, 429-435. https://doi.org/10.1097/MCP.0000000000000074
- Meltzer, E. B. and Noble, P. W. (2008) Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 3, 8.
- Miao, Y., Geng, Y., Yang, L., Zheng, Y., Dai, Y. and Wei, Z. (2022) Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating "PPAR-γ-glutaminolysis-DEPTOR" pathway in pulmonary fibrosis. J. Nutr. Biochem. 101, 108923.
- Miao, K., Pan, T., Mou, Y., Zhang, L., Xiong, W., Xu, Y., Yu, J. and Wang, Y. (2020) Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther. Adv. Chronic Dis. 11, 2040622320940185.
- Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D., Daigl, M., Kirchgaessler, K.-U., Lancaster, L., Leserer, D. J., Pereira, C. A., Swigris, J. J., Valeyre, D. and Noble, P. W. (2017) Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 5, 33-41. https://doi.org/10.1016/S2213-2600(16)30326-5
- Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Jr., Lancaster, L., Sahn, S. A., Szwarcberg, J., Valeyre, D. and du Bois R. M. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760-1769. https://doi.org/10.1016/S0140-6736(11)60405-4
- Olson, A. L. and Swigris, J. J. (2012) Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin. Chest Med. 33, 41-50. https://doi.org/10.1016/j.ccm.2011.12.001
- P, K. M., Sivashanmugam, K., Kandasamy, M., Subbiah, R. and Ravikumar V. (2021) Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors. Life Sci. 266, 118883.
- Pardo, A. and Selman, M. (2002) Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. Cell Biol. 34, 1534-1538. https://doi.org/10.1016/S1357-2725(02)00091-2
- Prashanth Goud, M., Bale, S., Pulivendala, G. and Godugu, C. (2019) Therapeutic effects of Nimbolide, an autophagy regulator, in ameliorating pulmonary fibrosis through attenuation of TGF-β1 driven epithelial-to-mesenchymal transition. Int. Immunopharmacol. 75, 105755.
- Pulivendala, G., Bale, S. and Godugu, C. (2020) Honokiol: a polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo. Toxicol. Appl. Pharmacol. 391, 114913.
- Qian, W., Cai, X., Qian, Q., Zhang, W. and Wang, D. (2018) Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J. Cell. Mol. Med. 22, 4354-4365. https://doi.org/10.1111/jcmm.13725
- Qu, Y., Zhang, G., Ji, Y., Zhua, H., Lv, C. and Jiang, W. (2016) Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. Phytomedicine 23, 350-358. https://doi.org/10.1016/j.phymed.2016.01.011
- Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D. M., Johkoh, T., Kim, D. S., King, T. E., Jr., Kondoh, Y., Myers, J., Muller, N. L., Nicholson, A. G., Richeldi, L., Selman, M., Dudden, R. F., Griss, B. S., Protzko, S. L. and Schunemann, H. J. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. of Respir. Crit. Care Med. 183, 788-824.
- Richeldi, L., Collard, H. R., and Jones, M. G. (2017) Idiopathic pulmonary fibrosis. Lancet 389, 1941-1952. https://doi.org/10.1016/S0140-6736(17)30866-8
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., SchlenkerHerceg, R., Disse, B. and Collard, H. R. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071-2082. https://doi.org/10.1056/NEJMoa1402584
- Selman, M., King, T. E. and Pardo, A. (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134, 136-151. https://doi.org/10.7326/0003-4819-134-2-200101160-00015
- Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Muller, V. and Kreuter, M. (2019) The therapy of idiopathic pulmonary fibrosis: what is next? Eur. Respir. Rev. 28, 190021.
- Sun, S. C., Han, R., Hou, S. S., Yi, H. Q., Chi, S. J. and Zhang, A. H. (2020) Juglanin alleviates bleomycin-induced lung injury by suppressing inflammation and fibrosis via targeting sting signaling. Biomed. Pharmacother. 127, 110119.
- Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takagashi, H., Nakata, K., Sato, A., Takeuchi, M., Raghu, G., Kudoh, S. and Nukiwa, T. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 21-29.
- Tao, L., Cao, J., Wei, W., Xie, H., Zhang, M. and Zhang, C. (2017) Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo. Int. Immunopharmacol. 47, 38-46. https://doi.org/10.1016/j.intimp.2017.03.020
- Tian, S. L., Yang, Y., Liu, X. L. and Xu, Q. B. (2018) Emodin attenuates bleomycin-induced pulmonary fibrosis via anti-inflammatory and anti-oxidative activities in rats. Med. Sci. Monit. 24, 1-10. https://doi.org/10.12659/MSM.905496
- Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A, Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., Behr, J., Bouros, D., Brown, K. K., Colby, T. V., Collard, H. R., Cordeiro, C. R., Cottin, V., Crestani, B., Drent, M., Dudden, R. F., Egan, J., Flaherty, K., Hogaboam, C., Inoue, Y., Johkoh, T., Kim, D. S., Kitaichi, M., Loyd, J., Martinez, F. J., Myers, J., Protzko, S., Raghu, G., Richeldi, L., Sverzellati, N., Swigris, J. and Valeyre, D. (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733-748.
- Tzouvelekis, A., Tzilas, V., Dassiou, M. and Bouros, D. (2018) Metformin in idiopathic pulmonary fibrosis "seeking the holy-grail through drug-repositioning". Respiration 96, 305-307. https://doi.org/10.1159/000490917
- Wang, L., Liu, H., He, Q., Gan, C., Li, Y., Zhang, Q., Yao, Y., He, F., Ye, T. and Yin, W. (2020a) Galangin ameliorated pulmonary fibrosis in vivo and in vitro by regulating epithelial-mesenchymal transition. Bioorg. Med. Chem. 28, 115663.
- Wang, Y., Dong, X., Zhao, N., Su, X., Wang, Y., Li, Y., Wen, M., Li, Z., Wang, C., Chen, J. and Zuang, W. (2020b) Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the wingless/integrase-1 signaling pathway. Exp. Lung Res. 46, 185-194. https://doi.org/10.1080/01902148.2020.1760964
- Williams, K. J. (2014) Gammaherpesviruses and pulmonary fibrosis: evidence from humans, horses, and rodents. Vet. Pathol. 51, 372-384. https://doi.org/10.1177/0300985814521838
- Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S. and Kolb, M. (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45, 1434-1445. https://doi.org/10.1183/09031936.00174914
- Xia, Y., Xia, Y. F., Lv, Q., Yue, M. F., Qiao, S. M., Yang, Y., Wei, Z. F. and Dai, Y. (2016) Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-gamma in colon. Br. J. Pharmacol. 173, 1219-1235. https://doi.org/10.1111/bph.13421
- Yang, F., Cao, Y., Zhang, J., You, T. and Zhu, L. (2017) Glaucocalyxin A improves survival in bleomycin-induced pulmonary fibrosis in mice. Biochem. Biophys. Res. Commun. 482, 147-153. https://doi.org/10.1016/j.bbrc.2016.11.003
- Yang, H., Hua, C., Yang, X., Fan, X., Song, H., Peng, L. and Ci, X. (2020) Pterostilbene prevents LPS-induced early pulmonary fibrosis by suppressing oxidative stress, inflammation and apoptosis in vivo. Food Funct. 11, 4471-4484. https://doi.org/10.1039/C9FO02521A
- Yang, J. Y., Tao, L. J., Liu, B., You, X. Y., Zhang, C. F., Xie, H. F. and Li, R. S. (2019) Wedelolactone attenuates pulmonary fibrosis partly through activating AMPK and regulating Raf-MAPKs signaling pathway. Front. Pharmacol. 10, 151.